CONCLUSION
Liposomes have developed into a viable pharmaceutical dosage form. Progress has taken place in quantum leaps, rather than in a continuum, over the last two decades.Vital progess have been made in the development of long circulating liposomes that are not immediately recognized and removed by the cells of mononuclear phagocyte system. Despit this long circulating liposomes have opned a new realm of therapeutic opportuities and we will see a multitude of novel applications emerge in future.
Development will continue to explore the validity of liposomes for the delivery of peptide and proteins, although progress in thid particular field has been meager.
These developments will hopefully safeguard against the overoptimistic and unrealistic ideas and promises of the past and lead into another highly productive and innovative phase of liposome research.